Iron-Metabolism Modifiers

Research on Iron pharmacology has produced a ready-to-market product (Fextract), while others are early-stage projects in search of partnership.
Fe list.jpg
Fe compara.jpg

Supplementary oral iron, especially at high dose, causes with GI disorders. Ferrous ions prompt oxidative stress and side-effects including nausea, flatulence, abdominal pain, diarrhoea or constipation, and black or tarry stools.

Other ‘soft’ food supplements might not properly restore the Iron storage.

Novel strategies of iron acquisition/limitation have been developed to afford high impact benefits to gastrointestinal microbiota and health-related condition. 

Fextract enhances the absorption iron entrapped in the current diet, preventing the iron overload in gut is suited to subjects intolerant or non-responder to oral iron. 

Fextract use during meal produces a net decrement of luminal Iron.

By this mean, iron-avid entheropatogens are disfavored while instead low-demanding bacteria such as Lactobacillus and Bifidobacterium spp. may find more space for competitive colonization.


Defemer is a irreversible enteral iron-sequestrant,  a potential therapy in dysbiosis and Fe-related gastrointestinal disorders, IBD and CRC.

It works beyond the current probiotics/prebiotics by high impact on microbiota.

Defemer is first-in-class therapeutic available in two versions:

- Water-soluble Fe-chelating polymer;

- Solid-state (insoluble) Fe-chelating resin 

Medical Device regulatory pathway allows fast-track to market with multiple indications after clinical validation, while further studies can be performed post-marketing. 

IP will be completed upon the licensing-out to industrial partners. 

Hemosiderin and iron overload are pathologic factor in diseases with defective microcirculation, also produced by the blood extravasation in interventions or trauma. 

Local iron depots catalyze the oxidative stress while also stimulate melanogenesis and HIF-1􏰃 protein output, thus stimulating its hypoxic/normoxic degradation. 

Hypofer (Trophoskin) chelates iron while recalls a hypoxic status leading to skin repair by increased expression of growth factors, angiogenesis and collagen production.